Pioglitazone, a PPAR-γ ligand, provides protection from dextran sulfate sodium-induced colitis in mice in association with inhibition of the NF-κB-cytokine cascade
Authors:
- Yuji NaitoYNYuji Naito
- Naoya TomatsuriNTNaoya Tomatsuri
- Osamu HandaOHOsamu Handa
- Hiroshi IchikawaHIHiroshi Ichikawa
- Norimasa YoshidaNYNorimasa Yoshida
- Toshikazu YoshikawaTYToshikazu Yoshikawa
- 1 October 2002
- journal article
- Published by Taylor & Francis in Redox Report
- Vol. 7 (5) , 283-289
Abstract
Nuclear factor-kappaB-dependent up-regulation of inflammatory cytokines occurs in inflammatory bowel disease. We investigated the effect of pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, on dextran sulfate sodium-induced colonic mucosal injury and inflammation in mice. Acute colitis was induced in female mice receiving 0, 1, 3, and 10 mg/kg i.p. of pioglitazone daily. Colonic mucosal inflammation was evaluated chemically and histologically. Thiobarbituric acid-reactive substances and tissue-associated myeloperoxidase activity were measured in intestinal mucosa as indices of lipid peroxidation and neutrophil infiltration, respectively. Colonic mRNA expression of pro-inflammatory cytokines and inducible nitric oxide synthase was measured by reverse transcription-PCR and nuclear factor-kappaB activation was evaluated by electrophoretic mobility shift assay. Dextran sulfate sodium administration resulted in decreases in body weight and colon length and increases in lipid peroxide and neutrophil accumulation of the intestine. In contrast, co-administration with pioglitazone prevented these changes. Transcripts coding for pro-inflammatory cytokines and inducible nitric oxide were expressed in high levels after the development of colitis, and pioglitazone markedly reduced mRNA expression of these genes. DNA binding activity of nuclear factor-kappaB was markedly increased, whereas in pioglitazone co-treated intestines the effect was significantly reduced. These data suggest that peroxisome proliferator-activated receptor-gamma may be a novel therapeutic target for the therapy of inflammatory bowel disease.Keywords
This publication has 33 references indexed in Scilit:
- Immunology of inflammatory bowel diseaseCurrent Opinion in Gastroenterology, 2000
- Nuclear factor-κB activity and intestinal inflammation in dextran sulphate sodium (DSS)-induced colitis in mice is suppressed by gliotoxinClinical and Experimental Immunology, 2000
- A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory responseJournal of Clinical Investigation, 1999
- Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein SlimbNature, 1998
- The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activationNature, 1998
- Peroxisome proliterator-activated receptors, orphans with ligands and functionsCurrent Opinion in Lipidology, 1997
- Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory DiseasesNew England Journal of Medicine, 1997
- PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS: A Nuclear Receptor Signaling Pathway in Lipid PhysiologyAnnual Review of Cell and Developmental Biology, 1996
- Local administration of antisense phosphorothiate olignucleotides to the p65 subunit of NF–κB abrogates established experimental colitis in miceNature Medicine, 1996
- A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in miceGastroenterology, 1990